JNJ · News · 20261014N

Innovative Medicine Growth

JOHNSON & JOHNSON · 2026-10-14 · Importance 55 · Surprise 32

Innovative Medicine grew 7.7% in the third quarter of 2026, materially outpacing MedTech’s 2.5% growth. Johnson & Johnson attributed the stronger pharmaceutical performance to accelerating launches and an expanding innovation pipeline. The segment’s growth was strong enough to support a more favorable outlook for the company’s pharmaceutical portfolio despite MedTech weakness.

Key facts